The combination of tezacaftor and ivacaftor in the treatment of patients with cystic fibrosis: clinical evidence and future prospects in cystic fibrosis therapy.

Ther Adv Respir Dis · 2019 · PMC6487765 · PMID 31027466

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

nominally significantno p-value reported

In EVOLVE, although nominally significant, there was a 5.1 point improvement in the CFQ-R respiratory domain score, and in EXPAND, the CFQ-R respiratory domain score increased by 11.1 points when compared with placebo.

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.